These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 36357960

  • 21. An evaluation of relugolix/estradiol/norethindrone acetate for the treatment of heavy menstrual bleeding associated with uterine fibroids in premenopausal women.
    Ali M, Chen HY, Chiang YF, Badary OA, Hsia SM, Al-Hendy A.
    Expert Opin Pharmacother; 2022 Mar; 23(4):421-429. PubMed ID: 35068291
    [Abstract] [Full Text] [Related]

  • 22. Oral Gonadotropin-Releasing Hormone Antagonists for the Treatment of Uterine Leiomyomas.
    Neblett MF, Stewart EA.
    Obstet Gynecol; 2023 May 01; 141(5):901-910. PubMed ID: 37103532
    [Abstract] [Full Text] [Related]

  • 23. Elagolix treatment in women with heavy menstrual bleeding associated with uterine fibroid: a systematic review and meta-analysis.
    Muhammad J, Yusof Y, Ahmad I, Norhayati MN.
    BMC Womens Health; 2022 Jan 15; 22(1):14. PubMed ID: 35033041
    [Abstract] [Full Text] [Related]

  • 24. Efficacy and safety of vilaprisan in women with uterine fibroids: data from the ASTEROID 3 randomized controlled trial.
    Al-Hendy A, Zhou YF, Faustmann T, Groettrup-Wolfers E, Laapas K, Parke S, Seitz C.
    F S Sci; 2023 Nov 15; 4(4):317-326. PubMed ID: 37437885
    [Abstract] [Full Text] [Related]

  • 25. Linzagolix with and without hormonal add-back therapy for the treatment of symptomatic uterine fibroids: two randomised, placebo-controlled, phase 3 trials.
    Donnez J, Taylor HS, Stewart EA, Bradley L, Marsh E, Archer D, Al-Hendy A, Petraglia F, Watts N, Gotteland JP, Bestel E, Terrill P, Loumaye E, Humberstone A, Garner E.
    Lancet; 2022 Sep 17; 400(10356):896-907. PubMed ID: 36116480
    [Abstract] [Full Text] [Related]

  • 26. Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary.
    Stewart EA, Lukes AS, Venturella R, Li Y, Hunsche E, Wagman RB, Al-Hendy A.
    J Comp Eff Res; 2024 Aug 17; 13(8):e230194. PubMed ID: 38934918
    [Abstract] [Full Text] [Related]

  • 27. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
    Muneyyirci-Delale O, Richard-Davis G, Morris T, Armstrong J.
    Clin Ther; 2007 Aug 17; 29(8):1682-91. PubMed ID: 17919549
    [Abstract] [Full Text] [Related]

  • 28. Vilaprisan in women with uterine fibroids: the randomized phase 2b ASTEROID 1 study.
    Bradley LD, Singh SS, Simon J, Gemzell-Danielsson K, Petersdorf K, Groettrup-Wolfers E, Ren X, Zvolanek M, Seitz C.
    Fertil Steril; 2019 Feb 17; 111(2):240-248. PubMed ID: 30527839
    [Abstract] [Full Text] [Related]

  • 29. The effectiveness of relugolix compared with leuprorelin for preoperative therapy before laparoscopic myomectomy in premenopausal women, diagnosed with uterine fibroids: protocol for a randomized controlled study (MyLacR study).
    Kitade M, Kumakiri J, Kobori H, Murakami K.
    Trials; 2024 May 24; 25(1):343. PubMed ID: 38790029
    [Abstract] [Full Text] [Related]

  • 30. A 12-month extension study to evaluate the safety and efficacy of asoprisnil in women with heavy menstrual bleeding and uterine fibroids.
    Diamond MP, Stewart EA, Williams ARW, Carr BR, Myers ER, Feldman RA, Elger W, Mattia-Goldberg C, Schwefel BM, Chwalisz K.
    Hum Reprod Open; 2019 May 24; 2019(4):hoz027. PubMed ID: 31777761
    [Abstract] [Full Text] [Related]

  • 31. Elagolix for the management of heavy menstrual bleeding associated with uterine fibroids: results from a phase 2a proof-of-concept study.
    Archer DF, Stewart EA, Jain RI, Feldman RA, Lukes AS, North JD, Soliman AM, Gao J, Ng JW, Chwalisz K.
    Fertil Steril; 2017 Jul 24; 108(1):152-160.e4. PubMed ID: 28579415
    [Abstract] [Full Text] [Related]

  • 32. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
    Laberge PY, Murji A, Vilos GA, Allaire C, Leyland N, Singh SS.
    J Obstet Gynaecol Can; 2019 Oct 24; 41(10):1521-1524. PubMed ID: 31548041
    [Abstract] [Full Text] [Related]

  • 33. Uterine volume and menstrual patterns in users of the levonorgestrel-releasing intrauterine system with idiopathic menorrhagia or menorrhagia due to leiomyomas.
    Magalhães J, Aldrighi JM, de Lima GR.
    Contraception; 2007 Mar 24; 75(3):193-8. PubMed ID: 17303488
    [Abstract] [Full Text] [Related]

  • 34. Oriahnn: New Drug Approved for Treating Heavy Menstrual Bleeding in Women With Uterine Fibroids.
    Lynch SE, Mayer DC.
    Ann Pharmacother; 2022 Jan 24; 56(1):93-101. PubMed ID: 33998300
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain.
    Blair HA.
    Drugs; 2024 Apr 24; 84(4):449-457. PubMed ID: 38592603
    [Abstract] [Full Text] [Related]

  • 38. Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
    Osuga Y, Enya K, Kudou K, Hoshiai H.
    Fertil Steril; 2019 Nov 24; 112(5):922-929.e2. PubMed ID: 31594635
    [Abstract] [Full Text] [Related]

  • 39. Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results.
    Osuga Y, Seki Y, Tanimoto M, Kusumoto T, Kudou K, Terakawa N.
    BMC Womens Health; 2021 Jun 21; 21(1):250. PubMed ID: 34154590
    [Abstract] [Full Text] [Related]

  • 40. Elagolix for Heavy Menstrual Bleeding in Women with Uterine Fibroids.
    Schlaff WD, Ackerman RT, Al-Hendy A, Archer DF, Barnhart KT, Bradley LD, Carr BR, Feinberg EC, Hurtado SM, Kim J, Liu R, Mabey RG, Owens CD, Poindexter A, Puscheck EE, Rodriguez-Ginorio H, Simon JA, Soliman AM, Stewart EA, Watts NB, Muneyyirci-Delale O.
    N Engl J Med; 2020 Jan 23; 382(4):328-340. PubMed ID: 31971678
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.